Upstate Active Clinical Trials
Study Title:A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus (T2DM)
What is the purpose of the study?The purpose of this study is to evaluate the effectiveness of insulin glargine/lixisenatide combination as compared with insulin glargine alone and with lixisenatide alone. The three treatments are self-injected once daily.
Upstate Institutional Review Board (IRB) Number:566461
Patient Age Group:Adults
Principal Investigator:Ruth S Weinstock, MD, PhD
What is involved if I participate?
- How long is the study?
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
- What tests and procedures are involved?
Procedures during study visits include: physical exams, vital signs, blood collection, urinalysis, ECG, questionnaire completion. Subjects will be asked to keep a diary of blood glucose readings throughout the study.
Where will the study take place?Clinical Research Unit at IHP (505 Irving Ave.)
Other Information:Study medications in pen form will be provided for the length of the study, along with a glucose meter and testing supplies
Who can I contact for more information?
Name: Jane D Bulger